Recent secondary market transactions have driven Neuralink’s implied valuation into the $42–60 billion range as of October 2026, well above its $9.7 billion post-money Series E in June 2025. This surge reflects sustained investor appetite for Elon Musk-linked assets, evidenced by secondary bids cited by Caplight and marks from PrivateMarketView near $59.8 billion, alongside clinical milestones including over 21 implants, transdural procedures, and voice-synthesis demonstrations. With resolution set for October 31, traders are monitoring any late-October funding updates or trial data releases that could shift private-market pricing, though the company remains pre-IPO and focused on regulatory pathways rather than public listings.